Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant
Deal Brings Pfizer Another Prostate Cancer Offering
Executive Summary
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
You may also be interested in...
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Deal Watch: Celgene CVR From BMS Buyout Falls Through
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports